Development of a four-item Migraine Specific Quality of life questionnaire (MSQ4) to evaluate the need for a migraine preventive treatment in general practice (GP)

被引：0
|
作者：
Lantéri-Minet, M
Pradalier, A
Valade, D
Vicaut, E
Delgado, A
Géraud, G
机构：
[1] Pasteur Hosp, Dept Evaluat & Treatment Pain, Nice, France
[2] Louis Mourier Hosp, Headache Ctr, Colombes, France
[3] Lariboisiere Hosp, Headache Urgency Ctr, Paris, France
[4] Fernand Vidal Hosp, Clin Res Unit, Paris, France
[5] Schwarz Pharma France, Boulogne, France
[6] Hop Rangueil, Dept Neurol, Toulouse, France
来源：
CEPHALALGIA | 2005年 / 25卷 / 10期
关键词：
migraine; preventive treatment initiation; quality of life;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
下载
收藏
页码：940 / 940
页数：1
相关论文
共 8 条
  • [1] Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment
    Cole, Jason C.
    Lin, Peggy
    Rupnow, Marcia F. T.
    QUALITY OF LIFE RESEARCH, 2007, 16 (07) : 1231 - 1237
  • [2] Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment
    Jason C. Cole
    Peggy Lin
    Marcia F. T. Rupnow
    Quality of Life Research, 2007, 16 : 1231 - 1237
  • [3] IMPROVEMENTS IN MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE (MSQ) DOMAIN SCORES WITH FREMANEZUMAB AND GALCANEZUMAB IN PATIENTS WITH MULTIPLE PRIOR MIGRAINE PREVENTIVE TREATMENT FAILURES: A NETWORK META-ANALYSIS
    Mu, F.
    Driessen, M. T.
    Cohen, J. M.
    Wang, Y.
    Ayyagari, R.
    VALUE IN HEALTH, 2021, 24 : S158 - S158
  • [4] Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study
    Shibata, Mamoru
    Nakamura, Tomomi
    Ozeki, Akichika
    Ueda, Kaname
    Nichols, Russell M.
    JOURNAL OF PAIN RESEARCH, 2020, 13 : 3531 - 3538
  • [5] Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients With Episodic Migraine by Galcanezumab Treatment: CGAN Japan Phase 2 Study
    Shibata, M.
    Nakamura, T.
    Kuga, A.
    Ozeki, A.
    Nichols, R. M.
    HEADACHE, 2020, 60 : 114 - 114
  • [6] Effect of atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-week, doubleblind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
    Lipton, R.
    Pozo-Rosich, P.
    Dodick, D.
    Christie, S.
    Ailani, J.
    Nagy, K.
    Stokes, J.
    Guo, H.
    Gandhi, P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [7] Effect of Atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-Week, Double-blind, Randomized, Phase 3 (PROGRESS) Trial for Preventive Treatment of Chronic Migraine
    Lipton, Richard B.
    Pozo-Rosich, Patricia
    Dodick, David W.
    Christie, Suzanne
    Ailani, Jessica
    Nagy, Krisztian
    Stokes, Jonathan
    Guo, Hua
    Gandhi, Pranav
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 87 - 89
  • [8] Effect of Atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-Week, Double-blind, Randomized, Phase 3 ( PROGRESS) Trial for Preventive Treatment of Chronic Migraine
    Lipton, R.
    Pozo-Rosich, P.
    Dodick, D.
    Christie, S.
    Ailani, J.
    Nagy, K.
    Stokes, J.
    Guo, H.
    Gandhi, P.
    HEADACHE, 2023, 63 : 126 - 127
1